Results 211 to 220 of about 185,906 (291)
Severe Dupilumab-Associated Psoriasis Flare After Switching From Ustekinumab for Biopsy-Proven Eczematous Dermatitis: A Case Report. [PDF]
AlAwadhi D +9 more
europepmc +1 more source
Plant‐derived nanovesicles (PDNVs) are naturally secreted by fruit, vegetables, seeds, leaves and other natural sources. Used as drug delivery systems, they can combine intrinsic therapeutic activity, enhanced skin permeation and cargo‐carrying capacity, suitable for dermatological and cosmetic applications including hydration, antioxidant/anti ...
Dorotea Fiore +5 more
wiley +1 more source
Type 17 T-cell subset divergence in hidradenitis suppurativa versus psoriasis: a comparative single-cell transcriptomic analysis. [PDF]
Park N +9 more
europepmc +1 more source
ABSTRACT Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, is approved in multiple countries for the treatment of moderate to severe plaque psoriasis, as well as generalized pustular and erythrodermic psoriasis in Japan. Deucravacitinib 6 mg once daily was efficacious and well tolerated through 3 years in the pooled population of ...
Yukari Okubo +12 more
wiley +1 more source
Peripheral γδ T-cell remodeling in psoriasis is associated with effector-biased transcriptional organization and reduced representation of a circulating <i>CSMD1</i>-marked state. [PDF]
Shi N +16 more
europepmc +1 more source
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro +3 more
wiley +1 more source
Qingre Liangxue Acupuncture for Psoriasis: A Cholinergic Neuroimmune Framework. [PDF]
Liu L, Liu W, Liu RJ.
europepmc +1 more source
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada +9 more
wiley +1 more source

